Brief: Alphamab Oncology Sees Profit Of Not Less Than RMB150.0 Million For Year
04/03/2025 14:29
March 4 (Reuters) - Alphamab Oncology 9966.HK: SEES PROFIT OF NOT LESS THAN RMB150.0 MILLION FOR YEAR EXPECTED RESULT DUE TO THREE LICENSE COLLABORATIONS AND SALES REVENUE IN FY Further company coverage: 9966.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)